摘要
目的:比较瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性。方法:96例冠心病患者随机均分为观察组和对照组。所有患者对饮食进行合理控制,同时服用低分子肝素、阿司匹林肠溶片、β受体阻滞药和硝酸酯类药物等常规治疗,但不服用维生素等抗氧化药物。在此基础上,观察组患者给予瑞舒伐他汀钙片10 mg,口服,每日1次;对照组患者给予阿托伐他汀钙胶囊20 mg,口服,每日1次。两组患者疗程均为6个月。观察两组患者的临床疗效,治疗前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、超敏C反应蛋白(hs-CRP)和左心射血分数(LVEF)及不良反应发生情况。结果:两组患者总有效率、不良反应发生率比较,差异均无统计学意义(P>0.05)。治疗前,两组患者TC、TG、LDL-C、HDL-C、hs-CRP、LVEF比较,差异均无统计学意义(P>0.05)。治疗后,两组患者TC、TG、LDL-C、hs-CRP均显著低于同组治疗前,且观察组TC、LDL-C、hs-CRP均低于对照组,HDL-C、LVEF均显著高于同组治疗前,且观察组均高于对照组,差异均有统计学意义(P<0.05)。结论:瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性均相当,但瑞舒伐他汀在降低血脂方面优于阿托伐他汀。
OBJECTIVE： To compare the efficacy and safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease. METHODS： 96 patients with coronary heart disease were randomly divided into observation group and control group. All patients received reasonable diet control, low molecular weight heparin, Aspirin enteric-coated tablet, I]-blockers, nitric acid lipids and other conventional treatment, but no vitamins and other anfioxidant drugs. Based on it, observation group was orally given 10 mg Rosuvastatin tablet, once a day; control group was given 20 mg Atorvastatin capsule, once a day. The treatment course for both groups was 6 months. Clinical efficacy, total cholesterol （TC） , triglyceride （TG） , low density lipoprotein cholesterol （LDL-C）, high density lipoprotein cholesterol （HDL-C）, high-sensitivity C-reactive protein （hs-CRP） and left ventricular ejection fraction （LVEF） before and after treatment, and the incidence of adverse reactions in 2 groups were observed. RESULTS： There were no significant differences in the total effective rate and incidence of adverse reactions between 2 groups（P〉0.05）. Before treat- ment, there were no significant differences in the TC, TG, LDL-C, HDL-C, hs-CRP and LVEF between 2 groups（P〉0.05）. After treatment, TC, TG, LDL-C, HDL-C and hs-CRP in 2 groups were significantly lower than before, and TC, LDL-C and hs-CRP in observation group were lower than control group, HDL-C and LVEF in 2 groups were significantly higher than before, and observa- tion group was higher than control group, the differences were statistically significant （P^0.05）. CONCLUSIONS： Rosuvastatin and atorvastatin has similar efficacy and safety in the treatment of coronary heart disease, but rosuvastatin is superior to atorvastatin in terms of reducing lipid levels.
出处
《中国药房》
CAS
北大核心
2016年第12期1611-1613,共3页
China Pharmacy
关键词
瑞舒伐他汀
阿托伐他汀
冠心病
疗效
安全性
Rosuvastatin
Atorvastatin
Coronary heart disease
Efficacy
Safety
